All News
Filter News
Found 808,645 articles
-
ASLAN Pharmaceuticals Reports First Quarter 2020 Financial Results and Provides Corporate Update
5/11/2020
ASLAN Pharmaceuticals, a clinical-stage immunology and oncology focused biopharmaceutical company developing innovative treatments to transform the lives of patients, reported financial results for the first quarter ended 31 March 2020 and provided an update on its clinical activities.
-
Matinas BioPharma Reports First Quarter 2020 Financial Results and Operational Highlights
5/11/2020
Matinas BioPharma Holdings, Inc., a clinical-stage biopharmaceutical company, reported financial results for the first quarter ended March 31, 2020, along with a corporate update and outlook for 2020.
-
Orexo Acquires Exclusive US Rights to Commercialize deprexis®, A World-leading Digital Therapy to Help Patients Manage the Symptoms of Depression
5/11/2020
Orexo AB announces it has acquired the exclusive US rights to GAIA AG's deprexis®, a digital therapy to help patients manage their symptoms of depression and one of the most researched digital therapies in the world.
-
Nephros, Inc. to Hold Virtual Annual Meeting of Stockholders
5/11/2020
Nephros, Inc. announced that, due to the public health concerns associated with the ongoing coronavirus outbreak and to support the health and well-being of its stockholders, employees, and other partners, the location of the 2020 Annual Meeting of Stockholders of Nephros, Inc. has been changed.
-
Evelo Biosciences Reports First Quarter Financial Results and Business Highlights
5/11/2020
Submitted investigational new drug (IND) application for a Phase 2 trial of EDP1815 for COVID-19; data readout expected during 2H 2020
-
REMINDER: Genocea to Host KOL Symposium Highlighting GEN-011’s Potential to Transform T cell Therapy for Solid TumorsCall scheduled for May 12th from 12:00 – 1:30 p.m. EDT
5/11/2020
Genocea Biosciences, Inc., a biopharmaceutical company developing next-generation neoantigen immunotherapies, will host a KOL symposium with a live Q&A for analysts and investors to reflect on the progress of the T cell therapy landscape and provide an in-depth profile of GEN-011 – Genocea’s neoantigen cell therapy – on Tuesday, May 12th at 12:00 p.m. EDT.
-
iCAD Reports First Quarter 2020 Financial Results
5/11/2020
Recent Equity Offering Strengthens Balance Sheet and Increases Operating Flexibility with focus on Brain Cancer Initiatives
-
Ultragenyx to Present at BofA Securities Global Health Care Conference
5/11/2020
Ultragenyx Pharmaceutical Inc., a biopharmaceutical company focused on the development of novel products for serious rare and ultra-rare genetic diseases, announced that Shalini Sharp, the company's Chief Financial Officer, will hold a virtual presentation at the BofA Securities Global Health Care Conference on Thursday, May 14, 2020 at 10:20 AM ET.
-
10x Genomics Reports First Quarter 2020 Financial Results
5/11/2020
10x Genomics, Inc. reported financial results for the quarter ended March 31, 2020.
-
Exagen Inc. Reports First Quarter 2020 ResultsAVISE® Testing Volumes Increase with Retention Rate of 99%
5/11/2020
Exagen Inc., an organization dedicated to transforming the care continuum for patients suffering from autoimmune diseases, reported financial results for the quarter ended March 31, 2020.
-
Instrumentation Laboratory Worldwide Sales Continue Upward Trajectory In 2019
5/11/2020
Instrumentation Laboratory announced total worldwide sales in 2019 of $1,096 M, with total growth of 7.6% over 2018, in local currencies.
-
Cellect Biotechnology Announces Positive Data Demonstrating Robust Engraftment Using ApoGraft was Featured in Bone Marrow Transplantation; Primary Data Points Were Submitted to the FDA During Investigational New Drug Approval Process
5/11/2020
Cellect Biotechnology Ltd. announced the publication of an article in Bone Marrow Transplantation, a peer-reviewed medical journal )member of the Nature publishing house) covering transplantation of bone marrow in humans and published monthly by the prestigious Nature Research, entitled 'Ex-vivo FAS-ligand to Improve Allograft Safety'.
-
bluebird bio Provides Operational and Business Update and Reports First Quarter 2020 Financial Results
5/11/2020
Alignment with FDA on an accelerated regulatory path for LentiGlobin for sickle cell disease based on HGB-206 study with targeted submission in 2H 2021
-
Sarepta Therapeutics and Dyno Therapeutics Announce Agreement to Develop Next-Generation Gene Therapy Vectors for Muscle Diseases
5/11/2020
Agreement leverages Sarepta’s leadership in gene therapy for neuromuscular and cardiovascular diseases and Dyno’s CapsidMap artificial intelligence platform to design AAV vectors
-
GW Pharmaceuticals plc Reports First Quarter 2020 Financial Results and Operational Progress
5/11/2020
GW Pharmaceuticals plc, a world leader in the science, development, and commercialization of cannabinoid prescription medicines, announces financial results for the first quarter ended March 31, 2020.
-
MyoKardia Announces Proposed Public Offering of Common Stock - May 11, 2020
5/11/2020
MyoKardia, Inc., a clinical-stage biopharmaceutical company discovering and developing targeted therapies for the treatment of serious cardiovascular diseases, announced that it has commenced a proposed underwritten public offering to sell $450.0 million in shares of its common stock.
-
LogicBio Therapeutics to Present New Data on GeneRide™ Platform and Next Generation Capsid Development Program at the American Society of Gene & Cell Therapy 2020 Annual Meeting
5/11/2020
Presentations Highlighting Novel Preclinical Methylmalonic Acidemia Model
-
Cara Therapeutics Reports First Quarter 2020 Financial ResultsConference call today at 4:30 p.m. ET
5/11/2020
Cara Therapeutics, Inc., a biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pruritus by selectively targeting peripheral kappa opioid receptors, or KORs, announced financial results and operational highlights for the first quarter ended March 31, 2020.
-
Cellectis’ Annual Shareholders’ General Meeting to be Held on June 29, 2020
5/11/2020
In the context of the COVID-19 epidemic and in accordance with Ordinance No. 2020-321 of March 25, 2020, the annual general meeting will take place on June 29, 2020 at 9 AM CET at Cellectis’ headquarters, located at 8, rue de la Croix Jarry, 4th floor, 75013 Paris, France behind closed doors, i.e. without the physical presence of the shareholders.
-
AdaptHealth Corp. to Present at Two Healthcare Conferences in May 2020
5/11/2020
AdaptHealth Corp., a leading provider of home healthcare equipment, medical supplies to the home and related services in the United States, announced that management will present at the following virtual healthcare conferences in May: